Maxx Chatsko

Repligen stands to lose all of its royalties on Orencia from Bristol-Myers Squibb in 2014. Here's what investors need to know.

The largest names in pharmaceuticals -- AbbVie, Roche, Pfizer, and Johnson & Johnson -- are being proactive in the search for the next game-changing therapeutics. Sometimes, that means reaching out to small, unheard-of companies. It's easy to forget that privately held companies make breakthroughs as well, but it would behoove biotech investors to keep an eye on these five disruptive companies.

Many investors have taken kindly to the potential of 3-D bioprinting company Organovo. While there is plenty of disruptive potential for the pharmaceutical applications of tissue engineering, let's not forget the myriad of other technologies within reach.

Total has invested heavily in the future of fuels, but that future looks quite different from most people's perception of oil. Can novel investments, such as synthetic biology pioneer Amyris, really drive future growth?

Third-quarter results are in for Air Lease. How do they compare to the company's industry peers?

Repligen enjoyed incredible growth in the third quarter, but is set to lose a significant revenue stream from Bristol-Myers Squibb at the end of the year. Does the good outweigh the bad?

Third quarter results are in at Solazyme. Will production delays disrupt the company's ambitious plans going forward?

Renewable Energy Group reported third quarter earnings and quelled investor fears over production gains, which have weighed on shares since September. Should investors be worried about a mega-facility from Darling International and Valero?

Shares of CARBO Ceramics have nearly doubled this year on the heels of an improving outlook for proppant demand, which has kept Hi-Crush Partners and U.S. Silica trekking higher all year long. Is the new valuation sustainable?

Repligen only has one product in manufacturing equipment, but it may be a better way to capitalize on the growing trend in biotech manufacturing than Amgen and General Electric.

Air Lease reports earnings this week. Can it continue to fly laps around Aircastle, AerCap Holdings, and Fly Leasing?

The results are in at CVR Partners, which survived a scare from Rentech Nitrogen last week. Can the two smaller producers make up ground between larger peer Terra Nitrogen?

The French energy giant may do most of its work in oil and gas, but Total's future could be determined by its ambitious renewable energy projects.

Here's what investors need to be looking for in Solazyme's next earnings call.

Dendreon's Provenge faces fierce competition from Johnson & Johnson, Medivation, and Bayer, but its manufacturing facilities could be sold individually. Would such a sale create enough value for shareholders?

Incyte has turned a lot of heads in the most recent quarter thanks to tremendous progress in partnerships with Novartis and Eli Lilly.

Amyris made steady progress in the third quarter with product sales to partners such as Cosan and collaboration revenue from energy giant Total, but shareholders were reminded about the importance of patience.

A questionable press release has sent shares of XOMA soaring today.

Wait -- tissue engineering can help save the planet AND bring back the Dollar Menu?

Politicians from both parties support raising gasoline taxes to pay for infrastructure improvements. It's a widely unpopular proposal, but with an estimated $3.6 trillion infrastructure deficit, someone has to budge.